(Q81463176)
Statements
A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis (English)
John D Bradley
Alexei A Dmitrienko
Alan J Kivitz
Oscar S Gluck
Arthur L Weaver
Craig Wiesenhutter
Stephen L Myers
Gregory D Sides